Previous Close | 0.8256 |
Open | 0.8900 |
Bid | 0.0000 x 800 |
Ask | 0.0000 x 900 |
Day's Range | 0.8803 - 0.9900 |
52 Week Range | 0.7200 - 7.0600 |
Volume | |
Avg. Volume | 48,778 |
Market Cap | 18.974M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.7210 |
Earnings Date | Mar 02, 2022 - Mar 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.00 |
BALTIMORE, May 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments and anticipated milestones, and reported financial results for the quarter ended March 31, 2022. Recent Corporate Developments Committed to advancing GB-102 into additional wet-AMD clinical trial — enhanced formulation of GB-102, designed to reduce o
BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a poster presentation of preclinical data for GB-401 in primary open-angle glaucoma (POAG) at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held at the Colorado Convention Center in Denver from May 1-4, 2022. Information is
Highlighted samples include 137 g/t Au over 0.56 mTORONTO, ON / ACCESSWIRE / April 26, 2022 /Graycliff Exploration Limited (the "Company" or "Graycliff") (CSE:GRAY)(OTCQB:GRYCF)(FSE:GE0) is pleased to announce field channel sampling results from its Phase 3 exploration program at Shakespeare Gold Project located on the prolific Canadian Shield near Sudbury, Ontario.